28th week of 2022 patent applcation highlights part 8 |
Patent application number | Title | Published |
20220218593 | SKIN WHITENING, ANTI-BACTERIAL OR ANTI-ATOPIC COMPOSITION, CONTAINING SYZYGIUM FORMOSUM EXTRACT AS ACTIVE INGREDIENT - Provided is a composition for skin whitening, including a | 2022-07-14 |
20220218594 | COSMETIC COMPOSITIONS - Disclosed is a method of improving a condition or appearance of skin. The method can include applying to skin an effective amount of a topical skin composition comprising tetrahexyldecyl ascorbate, | 2022-07-14 |
20220218595 | METHOD OF USING SOOTHING CREAM INCLUDING MACA ROOT EXTRACT AS AN ACTIVE INGREDIENT - Provided is a method of treating a penis of male human using a composition including a Maca root extract as an active ingredient to enhance erection of the penis. The method includes: applying an effective amount of the composition to a skin of a penis of a male human in need thereof. The composition comprises: a skin conditioner, a solvent, a humectant, a viscosity increasing agent, a surfactant, a preservative, a chelating agent, and perfume. The skin conditioner includes: a Maca root extract, a natural extract, niacinamide, glyceryl acrylate/acrylic acid copolymer, hyaluronic acid, arginine, hydrolyzed collagen, sucrose distearate, hydrogenated lecithin, and dimethicone. The composition includes: 0.5 to 10 parts by weight of the Maca root extract; and 1 to 5 parts by weight of the natural extract based on 100 parts by weight of the composition. | 2022-07-14 |
20220218596 | COMPOSITIONS FOR BEAUTY PRODUCTS AND METHODS OF MAKING SAME - A composition includes Aloe vera gel of 5% to 95% by weight of the composition; and sea moss of 5% to 95% by weight of the composition. A method includes the steps of obtaining a quantity of Aloe Vera plant; obtaining a quantity of sea moss; rinsing the sea moss with water for a period of 30 seconds to two minutes, wherein a temperature of the water is 95° F. to 115° F.; storing the sea moss in a refrigeration unit for a period of 4 hours to 36 hours; mixing the sea moss; storing the mixed sea moss in a refrigeration unit for a period of 4 hours to 36 hours; obtaining an interior gel of the Aloe vera plant; and mixing the sea moss with the Aloe vera gel. | 2022-07-14 |
20220218597 | COMPOSITIONS AND METHODS UTILIZING POLY(VINYL ALCOHOL) AND/OR OTHER POLYMERS THAT AID PARTICLE TRANSPORT IN MUCUS - Particles, compositions, and methods that aid particle transport in mucus are provided. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles including pharmaceutical agents that have a low water/aqueous solubility. In some embodiments, a surface coating includes a synthetic polymer having pendant hydroxyl groups on the backbone of the polymer, such as poly(vinyl alcohol) (PVA). Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier. | 2022-07-14 |
20220218598 | METHODS AND COMPOSITIONS FOR RAPID DELIVERY OF ANTI-SEIZURE THERAPEUTICS - Compositions for intranasal delivery of benzodiazepines and methods for their use to treat and prevent seizures are provided. The compositions deliver rapid therapeutic onset with a decreased incidence and/or severity of adverse effects after administration. Additionally, use of the compositions for the treatment of seizure clusters increases the time to a second seizure and duration of the interseizure cluster interval. | 2022-07-14 |
20220218599 | SELF-EMULSIFYING DRUG DELIVERY (SEDDS) FOR OPHTHALMIC DRUG DELIVERY - Provided herein are topical ophthalmic preparations which comprise a non-aqueous, self-emulsifying system which can spontaneously give rise to either nanosized emulsions upon contact with an aqueous phase. Also provided herein are methods for the preparation of the same and their use in formulating and delivering poorly water soluble drugs. | 2022-07-14 |
20220218600 | MEDICAL DEVICES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING ENHANCING COMFORT, ENHANCING DRUG PENETRATION, AND TREATMENT OF MYOPIA - The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures that alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating. | 2022-07-14 |
20220218601 | METHODS OF TREATING ALLERGIC CONJUNCTIVITIS - Disclosed is a sustained release biodegradable intracanalicular insert containing a glucocorticoid dispersed in a hydrogel. The insert is administered to a subject for the treatment of allergic conjunctivitis. | 2022-07-14 |
20220218602 | ORAL PHARMACEUTICAL COMPOSITION - The present invention provides an FTD and TPI-containing oral pharmaceutical composition which can be orally administered and is stable even under high humidity conditions. An oral pharmaceutical composition comprising α,α,α-trifluorothymidine and 5-chloro-6-(2-iminopyrrolidine-1-yl)methyl-2,4(1H,3H)-pyrimidine dione hydrochloride as an active ingredient; and being substantially free of an additive comprising a metal salt. | 2022-07-14 |
20220218603 | STABLE GEL COMPOSITION HAVING HIGH OIL CONTENT, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - A chewable stable gel composition having a high oil content, comprising, on the basis of the total weight of the composition, 55-70 wt % oil, 1-15 wt % first gelling agent, 0.1-2 wt % second gelling agent, 0.1-7 wt % stabilizer, optional other additives for medicine, food, and/or a health care product, and the balance of water. Also provided are a preparation method for and an application of the gel composition. | 2022-07-14 |
20220218604 | GASTRORETENTIVE DOSAGE FORMS FOR SUSTAINED DRUG DELIVERY - The present disclosure is directed to floating gastroretentive dosage forms with prolonged gastric residence time. The disclosure also provides rapidly expanding sustained release or combined immediate release and sustained release formulations comprising drugs that require targeted release in the proximal gastrointestinal tract for maximum therapeutic benefit. The rapidly expanding floating gastroretentive dosage forms comprise a permeable elastic membrane providing desired characteristics for drug release and mechanical strength to maintain tablet integrity. | 2022-07-14 |
20220218605 | BIFUNCTIONAL NUCLEOSIDE HYDROGEL, PREPARATION METHOD THEREFOR AND USE THEREOF - A bifunctional nucleoside hydrogel is formed by dissolving isoguanosine, guanosine and a borate in water or an aqueous solution and then crosslinking same. The bifunctional nucleoside hydrogel integrates a carrier and a drug effect and has a significant inhibitory effect on the activity of tumor cells, and in particular has a significant inhibitory effect on the activity of cells related to lung cancer, glioma, osteoma, colon cancer, breast cancer, oral squamous cell carcinoma and tongue squamous cell carcinoma, of which the inhibitory effect on the activity of cells related to oral squamous cell carcinoma is the best. Therefore, the bifunctional nucleoside hydrogel has potential application prospects in preparing anti-tumor drugs, and particularly, same can provide a new approach for treating oral squamous cell carcinoma. | 2022-07-14 |
20220218606 | READY TO USE DICLOFENAC STICK PACKS - Ready to use liquid formulations of diclofenac potassium are disclosed which are particularly well suited for packaging in stick-packs. | 2022-07-14 |
20220218607 | STABLE, LOW-VISCOSITY ANTIBODY FORMULATIONS AND USES THEREOF - Provided herein are aqueous antibody formulations that exhibit improved stability and low viscosity. The formulations include an antibody or an antigen-binding fragment, a buffer, and a salt selected from the group of magnesium glutamate, magnesium acetate, magnesium aspartate, magnesium sulfate, arginine acetate, arginine aspartate, arginine glutamate, arginine sulfate, lysine acetate, lysine aspartate, lysine glutamate, lysine sulfate, sodium acetate, sodium aspartate, sodium glutamate, sodium sulfate, lithium acetate, lithium aspartate, lithium glutamate, or lithium sulfate, where the formulations have a pH of about 4 to about 8 and, optionally an osmolality of about 250 mOsm/kg to about 1500 mOsm/kg | 2022-07-14 |
20220218608 | INJECTABLE POLYMER NANOPARTICLE COMPOSITIONS OF ANTITHROMBOTIC AGENTS AND METHODS THEREOF - Disclosed are injectable nanoparticle compositions comprising a micelle formulation of an antithrombotic agent and a water-soluble, biodegradable, and amphiphilic polymer that improves water solubility of the antithrombotic agent. A method of preparing the injectable nanoparticle compositions and methods for preventing or treating thrombotic diseases such as venous thromboembolisms and/or stroke using the compositions, as well as devices and kits suitable for such treatment, are also disclosed. | 2022-07-14 |
20220218609 | EXOSOME SYSTEMS, PRODUCTS AND METHODS - The present disclosure relates to exosome systems and compositions and preservative systems and compositions as well as methods of use and methods of manufacturing of them. | 2022-07-14 |
20220218610 | TREATMENT OF HIP PAIN WITH SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONS - In some embodiments provided herein is a method of treating hip pain in a subject, the method comprising administering into the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome. | 2022-07-14 |
20220218611 | LIPID VESICLE COMPOSITIONS WITH PENETRATION ENHANCING AGENTS - The present application is related to a pharmaceutical composition a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more surfactants; one or more compounds; and one or more penetration enhancing agents. The one or more penetration enhancing agents include one or more non-ionic surfactants having a hydrophilic-lipophilic balance (HLB) of about 10 or less, alone or combination with one or more penetration enhancing agents selected from one or more of terpenes, alkaloids, salicylate derivatives, and polycationic surfactants and combinations thereof. The present application is also related to a pharmaceutical composition comprising a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more polycationic surfactants; and one or more compounds. | 2022-07-14 |
20220218612 | IMPROVED PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES - The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process for enhanced encapsulation of messenger RNA (mRNA) in lipid nanoparticles comprising a step of heating the mRNA-encapsulated lipid nanoparticles in a drug product formulation solution. | 2022-07-14 |
20220218613 | TREATMENT OF HIP PAIN WITH SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONS - In some embodiments provided herein is a method of treating hip pain in a subject, the method comprising administering into the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome. | 2022-07-14 |
20220218614 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF SYNTHESIS AND USE THEREOF - Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., immune cells), and methods of making and using such lipids and targeted lipid nanoparticles. | 2022-07-14 |
20220218615 | SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME - Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use. | 2022-07-14 |
20220218616 | TABLET AND METHOD FOR PRODUCING TABLET - Provided are a tablet and a method for producing the tablet, in particular, a technique for tablet production whereby the amount of an active ingredient to be contained in the tablet can be stably regulated without the need of a huge cost for the production. The tablet of the present invention is one obtained by compacting a mixture comprising a granulating composition including a medicinal ingredient or a biofunctional ingredient, and includes a first region, which comprises a binder including the medicinal ingredient or biofunctional ingredient, and a second region, which is adjacent to the first region and comprises the binder including the medicinal ingredient or biofunctional ingredient. The medicinal ingredient or biofunctional ingredient contained in each of the first region and second region is included in the binder, not in the form of a layer but in the state of having been dispersed or dissolved. | 2022-07-14 |
20220218617 | METHOD FOR MANUFACTURING PHARMACEUTICAL PREPARATION - Problem to be Solved | 2022-07-14 |
20220218618 | DOSING SYSTEM FOR CONTROLLED SUBSTANCES RELEASE BY MEANS OF DOSING MEMBRANES - The membrane dosing system for controlled release of substances from the container provides controlled release characteristics (delayed, prolonged and intensity) of one or more active substances from one or more different parts of the same container housed in a medium that dissolves (erodes) membranes into an environment. The dosage system shown consists of three basic parts, two outer elements ( | 2022-07-14 |
20220218619 | FILM, CAPSULE AND FILM-FORMING COMPOSITION COMPRISING WATER-SOLUBLE SALT AS OPACIFYING AGENT - Problem to be solved: To provide a whitened or opacified capsule and film without using a white pigment such as titanium dioxide. Solution: A film, a capsule and a film-forming composition characterized by containing a film-forming polymer component selected from gelatin and pullulan and an opacifying agent consisting of a water-soluble salt except calcium salt carbonate and bicarbonate, wherein the salt is selected from a sodium salt, potassium salt, an ammonium salt and a magnesium salt. | 2022-07-14 |
20220218620 | SOFT GEL COMPOSITIONS AND CAPSULES MADE FROM THE SAME - Film-forming compositions for soft capsule formation have from 2 to 20 percent by weight of a mixture of hydroxyalkylated plant starch and a plant sugar, from 15 to 25 percent by weight agar, no more than 5 percent by weight gelatin, no more than 1 percent by weight carrageenan, and water as the balance thereof. Soft capsules made from such a film-forming composition and methods of making the same are also disclosed. | 2022-07-14 |
20220218621 | EXTRACELLULAR VESICLES FOR DELIVERING THERAPEUTIC OR DIAGNOSTIC DRUGS - Extracellular vesicles isolated from blood plasma of oncological patients for selectively delivering therapeutic or diagnostic drugs are provided. Methods for isolating extracellular vesicles from an isolated sample of blood plasma and for preparing an isolated sample of blood plasma from oncological patients are also provided. | 2022-07-14 |
20220218622 | IONIZABLE LIPIDS AND METHODS OF MANUFACTURE AND USE THEREOF - The invention encompasses novel ionizable lipids compounds and their use in lipid nanoparticles delivery systems that are useful in the delivery of nucleic acids to a mammalian subject that can be included for use, for example, as cancer vaccines, gene editing therapeutics, delivery of nucleic acid (e.g., mRNA) encoding antibodies, vaccines for infectious disease, and protein replacement therapeutics. Additionally, the invention encompasses compositions and therapeutics comprising the ionizable lipids in the lipid nanoparticles and the use of the composition and therapeutics for the preparation of a pharmaceutical composition, especially a vaccine, (e.g., for use in the prophylaxis or treatment of infectious diseases, tumor or cancer diseases, rare diseases, allergies, or autoimmune diseases). The invention encompasses methods of treatment or prophylaxis of the aforementioned diseases. | 2022-07-14 |
20220218623 | TRANSDERMAL DELIVERY OF LARGE AGENTS - Methods, compositions, and devices for enhancing transdermal delivery of large agents. | 2022-07-14 |
20220218624 | INCLUSION COMPOUND CONTAINING NON-PSYCHOACTIVE CANNABINOID AND METHOD FOR PREPARTION THEREOF - Disclosed are an inclusion compound containing a non-psychoactive cannabinoid, and a method for preparation thereof. The inclusion compound is prepared by means of the following method: a cannabis extract is subjected to, in sequence, dissolving in organic solvent, incorporation of inclusion agent, analysis and removal of impurities in water-organic solvent, and vacuum drying and precipitation, and thus obtained. In the inclusion compound, psychoactive ingredients such as tetrahydrocannabidiol (THC) and Δ9-tetrahydrocannabinol (THCV) may be completely removed, effectively enriching the non-psychoactive ingredients such as cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), and so on with a total content of greater than 50%. The processing technique of the preparation method is simple to perform, and is conducive to commercialization. | 2022-07-14 |
20220218625 | TREATMENT OF BEHAVIORAL IMPAIRMENT IN DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY - The present technology relates to methods of treating behavioral problems and seizures in a subject having developmental and epileptic encephalopathy (DEE) by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein behavioral problems are treated in the subject. | 2022-07-14 |
20220218626 | ORAL ADMINISTRATION OF KETAMINE - Disclosed are pharmaceutical compositions having a portion of ketamine for intraoral release and another ketamine for gastrointestinal release. The compositions can further include aspirin. The disclosed formulations and related administration approaches improve the bioavailability and efficacy of oral ketamine. | 2022-07-14 |
20220218627 | INTRANASAL ADMINISTRATION OF KETAMINE TO CLUSTER HEADACHE PATIENTS - Provided is a method of treating patients with Cluster Headache (CH) including chronic Cluster Headache (cCH) comprising intranasal administration to a patient in need thereof of an aqueous composition, e.g., pharmaceutical composition, comprising a therapeutically effective amount of ketamine, which may reduce or eliminate side effects of ketamine when used in the treatment of Cluster Headache, and to a composition, e.g., pharmaceutical composition, comprising a therapeutically effective amount of ketamine for use in the treatment of Cluster Headache, wherein the composition is in a nasal dosage form such as a nasal spray. | 2022-07-14 |
20220218629 | EPINEPHRINE FINE PARTICLES AND METHODS FOR USE THEREOF - Compositions include epinephrine fine particles, including epinephrine nanoparticles or nanocrystals and epinephrine microparticles or microcrystals, and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine fine particles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. | 2022-07-14 |
20220218630 | METHODS AND FORMULATIONS FOR TREATING VISION DISORDERS - Ocular formulations comprising long-acting β-adrenoceptor agonist (LABA) compounds, long-acting muscarinic antagonists (LAMA), and combinations thereof are provided. Methods for treating vision disorders, with LABAs, LAMAs, and combinations thereof are also provided. | 2022-07-14 |
20220218631 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2022-07-14 |
20220218632 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF - The present disclosure generally relates to pharmaceutical compositions and combinations comprising an androgen receptor N-terminal domain inhibitor or an inhibitor and a second therapeutically active agent, such as an CDK4/6 inhibitor, a Pin1 inhibitor (inhibitor of peptidyl-prolyl cis/trans isomerases), or an antiandrogen. In particular, the present disclosure relates to pharmaceutical compositions and combinations useful for treatment of various cancers, for example breast cancer and prostate cancer. Further, the present disclosure relates administering an androgen receptor N-terminal domain inhibitor in combination with radiation therapy for treatment of various cancers. | 2022-07-14 |
20220218633 | COMPOUND AND COMPOSITION FOR USE IN THE TREATMENT OF PREMENSTRUAL SYNDROME AND/OR PREMENSTRUAL DYSPHORIC DISORDER - This invention pertains to a compound and a composition for use in the treatment of premenstrual syndrome and/or premenstrual dysphoric disorder. | 2022-07-14 |
20220218634 | METHOD FOR INDUCING MASS APOPTOSIS OF CANCER CELLS BY ENHANCING THE OVERALL ACIDITY IN THE TUMOR - A method for inducing mass apoptosis of cancer cells by enhancing the overall acidity in the tumor. The method enhances overall acidity in tumor internal tissue to reduce overall pH in tumor tissue, last to induce mass apoptosis of cancer cells. When pH of extracellular micro-environment of cancer cells is lower than 5.0, mass apoptosis of cancer cells can be induced. Base on the same direction synergic interaction between the changes of intracellular and extracellular acidity in tumor, the method may be achieved by injecting acid directly into tumor cells, or aggravating the anaerobic respiration of cancer cells through hyperthermia and other ways to enhance overall acidity in tumor tissues. The method may effectively induce mass apoptosis of cancer cells with little damaging to the normal cells, so as to inhibit the differentiation and proliferation of cancer cells, stop the metastasis and diffusion, and realize the radical cure of tumor. | 2022-07-14 |
20220218635 | KETONE SUPPLEMENTS-EVOKED EFFECT ON ABSENCE EPILEPSY BY CO-ADMINISTRATION OF URIDINE - Disclosed are methods of treating seizures in a subject. The methods can include administering to the subject in need thereof an effective amount of uridine source and a ketogenic composition including a ketogenic compound. | 2022-07-14 |
20220218636 | CONTROLLING BIOFILMS WITH CYCLOPROPANATED FATTY ACIDS - Compositions and methods for using cyclopropanated structural analogs of fatty acid biofilm dispersal agents are characterized by superior biofilm dispersion. When used in combination with antimicrobials, these analogs decrease the minimum inhibitory concentration of antimicrobial agents required for eradication of the biofilm and/or treatment of infection. Methods for using these analogs include direct application to a surface, blending with lipid based carriers, or covalent anchoring the molecule to a surface. Typically, the cyclopropanated structural analog has the structure according to formula (I): | 2022-07-14 |
20220218637 | Volatile Organic Compound Formulations Having Antimicrobial Activity - The present subject matter includes novel chemical formulations having antimicrobial, antifungal, antiseptic, and related effect in a wide range of applications for treating or preventing infections as well as treating various surfaces that may become tainted with infectants. In some embodiments, the formulation includes isoamyl hexanoates and at least one of propanoic and/or isobutyric acid. | 2022-07-14 |
20220218638 | Sensorineural Hair Cell Differentiation - The present disclosure provides compositions and methods for treating subjects at risk for or with sensorineural hearing loss. Such compositions and methods include modulating the epigenetic status of the cell, or rate of protein degradation, to increase expression and/or levels of Atoh1 protein. | 2022-07-14 |
20220218639 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS - Compositions and methods for therapeutic delivery are disclosed. More particularly, the present disclosure relates to nanoparticle compositions that sequester the activity of a target molecule while leaving other domains accessible to bind targeted tissues of interest. Methods for thrombus dissolution include administering a nanoparticle reversibly coupled to a target molecule that can dissolve a blood clot. Compositions and methods for inducing blood clotting are also disclosed. Methods for inducing blood clotting include administering a nanoparticle reversibly coupled to a target molecule that can induce the formation of a blood clot. Methods for sequestering a target molecule are also disclosed. The method includes reversibly coupling a target molecule to a nanoparticle having an affinity ligand that reversibly couples the target molecule, and thus, sequesters the target molecule activity until the target molecule interacts with its substrate resulting in the release of the target molecule. | 2022-07-14 |
20220218640 | AMINO ACID DELIVERY SYSTEM - An amino acid delivery system contains the essential amino acids, leucine, isoleucine, and valine in a complete amount that is indigestible in a single dose. The delivery system also includes other beneficial nutrients like vitamin C and vitamin B. Double doses accommodate larger bodies. The amino acids are combined in ratios that allow them to be mutually supportive. This combination ratio allows the body to absorb and use the nutrients at a greater rate. This blend of nutrients is indicated to reduce/prevent traumatic brain injury when taken prior to contact sports and enhance recovery after any form of traumatic brain injury. | 2022-07-14 |
20220218641 | METHODS OF TREATMENT WITH DEUTERATED ANALOGS OF D-SERINE - This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use. | 2022-07-14 |
20220218642 | Compositions And Methods For Prevention And Reduction Of Traumatic Brain Injury - Compositions and methods are presented that, upon administration prior to trauma, are effective to prevent and/or reduce severity of sequelae of TBI upon trauma. Advantageously, the compositions presented herein can be orally administered, have an excellent safety profile, and will not require a prescription by physician or hospital admission. | 2022-07-14 |
20220218643 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES - The present invention relates to the treatment of ocular diseases in a human subject In particular, the invention relates to an intracameral administration of a sustained release biodegradable intracameral implant. | 2022-07-14 |
20220218644 | METHOD AND COMPOSITION FOR TREATING OSTEOARTHRITIS - A method and composition for treating osteoarthritis including administering an anti-inflammatory agent to a patient, wherein the anti-inflammatory agent is ethyl (α-guanido-methyl) ethanoate. Ethyl (α-guanido-methyl) ethanoate provides a safe, non-toxic anti-inflammatory treatment for osteoarthritis. | 2022-07-14 |
20220218645 | Application of Trans-1,3-Dilinolein in the Preparation of Medicaments for Treating Gastric Cancer, Stomachic Tonic, Health Products and Foods - Some embodiments of the disclosure provide new uses of trans-1,3-dilinolein as medicaments and food. In an embodiment, an application of trans-1,3-dilinolein in the preparation of stomachic tonic and an application thereof include the preparation of medicaments for treating gastric cancer. Cell experiments show that trans-1,3-dilinolein promotes the proliferation of human gastric mucosal epithelial cell line GES-1 under normal oxygen and hypoxic conditions and it has concentration-dependent killing effect on human gastric cancer cell line HGC-27 and killing effect on hypoxic gastric cancer cells. At a concentration of 300 μm and more, trans-1,3-dilinolein kills gastric cancer cells significantly and the killing effect becomes more significant under hypoxic conditions. | 2022-07-14 |
20220218646 | DIETARY BUTYRATE AND ITS USES - Use of a compound having the formula (1), (2), (3) or (4), or combinations thereof, for providing a source of butyrate with improved organoleptic properties wherein R | 2022-07-14 |
20220218647 | DIETARY BUTYRATE | 2022-07-14 |
20220218648 | Mebeverine as soluble epoxy hydrolase inhibitor - The present invention relates to a method of using Mebeverine as an sEH inhibitor. The present invention also provides a method of treating metabolic and cardiovascular disorders using Mebeverine. | 2022-07-14 |
20220218650 | COMPOSITION AND METHOD FOR TREATING PAIN - The invention relates to pharmaceutical compositions comprising Δ | 2022-07-14 |
20220218651 | CANNABIDIOL COMPOSITIONS HAVING MODIFIED CANNABINOID PROFILES - The present disclosure relates to the preparation of a highly pure cannabidiol compound by a novel synthesis route. The cannabidiol compound can be prepared by an acid-catalyzed reaction of a di-halo olivetol with menthadienol, followed by two crystallization steps. The highly pure cannabidiol compound is produced in high yield, stereospecificity, or both, and shows exceedingly low levels of Δ-9-tetrahydrocannabinol at the time of preparation and after storage. | 2022-07-14 |
20220218652 | METHODS OF TREATING CYTOKINE RELEASE SYNDROME - The present disclosure relates to a method of treating at least one Cell-Associated Neurotoxicity Syndrome (ICANS), cancer-related cognitive impairment, Infusion Reaction Syndrome (IRS), Capillary Leak Syndrome (CLS), Tumor Lysis Syndrome (TLS), Macrophage Activation Syndrome (MAS), Systemic Inflammatory Response Syndrome (SIRS), Immune Reconstitution Inflammatory Syndrome (IRIS), Graft-Versus-Host Disease (GVHD), Acute Respiratory Distress Syndrome (ARDS), sepsis, Ebola, avian influenza, smallpox, Systemic Inflammatory Response Syndrome (SIRS), and Immune-related Adverse Events Syndrome (IrAES) in a subject in need thereof, comprising administering a mast cell stabilizer or a compound of Formula I or Formula II: Formula I, Formula II, wherein R | 2022-07-14 |
20220218653 | CARTRIDGE FOR VAPOR-PHASE CANNABINOID REACTIONS WITHIN A DEVICE - Disclosed herein is a cartridge for a vape device. The cartridge comprises a housing defining an inlet, an outlet, and an interior chamber that is position between the inlet and the outlet. The inlet, the outlet, and the interior chamber are fluidly connected by a flow path, and the inlet is configured to receive a first cannabinoid. The cartridge also comprises a Lewis-acidic heterogeneous reagent positioned in the interior chamber such that when the flow path passes through the interior chamber, at least a portion of the flow path contacts the Lewis-acidic heterogeneous reagent. The Lewis-acidic heterogeneous reagent has an acidity metric that surpasses a threshold acidity metric for the first cannabinoid such that contact between the Lewis-acidic heterogeneous reagent and the first cannabinoid under reaction conditions defined by a contact temperature and a contact time converts at least a portion of the first cannabinoid into a second cannabinoid. | 2022-07-14 |
20220218654 | ANTIBIOTIC CANNABINOID-TERPENE FORMULATIONS - Pharmaceutical formulations are provided that include at least two antibiotically active ingredients: a cannabinoid that is one or more of cannabichromene (CBC), cannabidiol (CBD) and/or cannabigerol (CBG); a sesquiterpene that is one or both of α-humulene and/or β-caryophyllene; and a lipopeptide antibiotic that is daptomycin or an analogue thereof. The antibiotically active ingredients may be provided in relative amounts that amplify their individual activities, including amounts that are synergistically effective in an assay to inhibit growth and/or reproduction of an | 2022-07-14 |
20220218655 | COMPOSITION USING 4',6,7-TRIMETHOXYISOFLAVONE AND CATECHOL FOR MANAGING PULMONARY FIBROSIS - Proposed is a composition for managing pulmonary fibrosis. The composition uses 4′,6,7-trimethoxyisoflavone and catechol that does not cytotoxicity and inhibits a TGF-β1 signal transfer pathway, thereby exhibiting EMT inhibitory activity. | 2022-07-14 |
20220218656 | METHOD FOR PURIFYING CANNABINOIDS - The invention relates to a method for the chromatographic purification of at least one cannabinoid compound, wherein the method comprises a main purification stage comprising the steps of: injecting an initial mixture comprising the at least one cannabinoid compound and one or more additional compounds onto a main stationary phase comprising silica particles, the silica particles comprising amino and/or diol groups; performing an elution with an elution solution, and collecting one or more elution fractions; and optionally, washing the main stationary phase with a washing solution and collecting one or more washing fractions; at least one of the elution fractions or washing fractions containing the at least one cannabinoid compound purified from the one or more additional compounds. | 2022-07-14 |
20220218657 | CANNABIS EXTRACTS AND METHODS OF PREPARING AND USING SAME - The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from | 2022-07-14 |
20220218658 | USE OF DELTA-TOCOTRIENOL IN TH PREVENTION OF CANCER AND CANCER RECURRENCE - Disclosed are compositions and methods for inhibiting cancer metastasis or a cancer recurrence in a subject following surgical removal or anti-cancer treatment of a cancer, comprising administering to the subject a composition comprising δ-tocotrienol (d-T3). Also disclosed are methods of determining if a subject is at risk for developing cancer metastasis or recurrence by measuring levels of hCAS expression and an optional treatment step if the subject is identified as being at risk for cancer metastasis or recurrence. | 2022-07-14 |
20220218659 | PI3K/LYN-ACLY Signaling Inhibition - The present disclosure is directed, in part, to pharmaceutical compositions comprising a Src protein tyrosine kinase inhibitor, an ATP citrate lyase (ACLY) inhibitor, and a PI3K inhibitor, and/or a Src and PIP | 2022-07-14 |
20220218660 | COMPOSITION FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER, COMPRISING QUASSINOIDS - The present invention relates to: a composition for treating castration-resistant prostate cancer, comprising quassinoids; and a method for treating castration-resistant prostate cancer by using same. | 2022-07-14 |
20220218661 | COMPOSITIONS AND METHODS FOR MODULAR CONTROL OF BIOORTHOGONAL LIGATION - The present invention provides a compound having the structure: | 2022-07-14 |
20220218662 | COMBINED MAPK AND NAMPT INHIBITION FOR TREATMENT OF NEURON DEGENERATION - Provided herein are methods for inhibiting or preventing neuron injury or death. The methods comprise contacting one or more neurons with small molecule modulators of one or more mitogen-activated kinase kinase kinases (MAP3Ks), a nicotinamide phosphoribosyltransferase (NAMPT), or a combination thereof. | 2022-07-14 |
20220218663 | METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-I - The present invention relates to a method of preventing and/or treating chronic traumatic encephalopathy. | 2022-07-14 |
20220218664 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG - A drug containing a compound represented by formula (I) as an active ingredient, used for complications from diabetes. | 2022-07-14 |
20220218665 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION - This invention relates to treating age-related cognitive impairment. This invention in particular relates to the use of inhibitors of synaptic vesicle protein 2A (SV2A), such as levetiracetam, seletracetam, and brivaracetam, in improving cognitive function in subjects that exhibit age-related cognitive impairment or are at risk thereof, including, without limitation, subjects having or at risk for Mild Cognitive Impairment (MCI), Age-related Cognitive Decline (ARCD) or Age-Associated Memory Impairment (AAMI). | 2022-07-14 |
20220218666 | APPLICATION OF TEGASEROD IN PREPARATION OF ANTI-TUMOR DRUG - The present disclosure discloses the use of Tegaserod or a pharmaceutically acceptable salt thereof as a JAK-STAT3 signaling pathway inhibitor and an immunomodulator in the preparation of an anti-tumor drug. Tegaserod and the pharmaceutically acceptable salt thereof show a very excellent inhibitory effect on the growth of various tumor cells in vivo and in vitro, and are expected to be used in the treatment of various cancers. | 2022-07-14 |
20220218667 | DUAL INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND METHODS OF USE THEREOF - Disclosed herein are methods to treatment of inflammatory and fibrotic progression, for example, idiopathic pulmonary fibrosis (IPF) with a dual inhibitor of soluble epoxide hydrolase inhibitors (sEH) and a secondary target. In particular, the invention relates to treatment of fibrotic progression with a dual inhibitor of sEH and COX-2. In one embodiment, IPF is treated with 4-(5-phenyl-3-{3-[3-(4-trifluoromethyl-phenyl)-ureido]-propyl}-pyrazol-1-yl)-benzenesulfonamide (PTUPB) or a derivative thereof. Also disclosed herein are compositions useful in treatment of fibrotic progression. | 2022-07-14 |
20220218668 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION - The present disclosure provides compositions and methods for inhibiting respiratory viral infections, inflammatory diseases, and/or respiratory inflammation. | 2022-07-14 |
20220218669 | COMPOSITIONS AND METHODS FOR NON-SURGICAL TREATMENT OF PTOSIS - Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis. | 2022-07-14 |
20220218670 | METHODS OF TREATING DISEASES CHARACTERISED BY VASOCONSTRICTION - There is herein provided a compound that is an mPGES-1 inhibitor, or a prodrug thereof, for use in the treatment or prophylaxis of a disease or disorder characterised by vasoconstriction. | 2022-07-14 |
20220218671 | TELMISARTAN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE IN DOGS - The present invention relates to telmisartan or a pharmaceutically acceptable salt thereof as a medicament for the treatment of elevated urinary protein-to-creatinine ratio (UPC) levels in dogs, wherein the therapeutically effective amount of telmisartan is administered in a daily dosage amount that is varied over a treatment period. | 2022-07-14 |
20220218672 | Thromboxane Receptor Antagonists in AERD/Asthma - The present invention is directed to methods of treating AERD (aspirin exacerbated respiratory disease) and/or asthma via the administration of a thromboxane receptor antagonist to a patient in need thereof. | 2022-07-14 |
20220218673 | USE OF RILUZOLE ORAL DISINTIGRATING TABLETS FOR TREATING DISEASES - Disclosed are methods of treating a disease in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of riluzole, or a pharmaceutically acceptable salt thereof, in the form of an oral solid molded fast-dispersing dosage form. Pharmaceutical compositions and kits are also disclosed. | 2022-07-14 |
20220218674 | TREATMENT OF VASCULAR AND LYMPHATIC DISEASE - Disclosed herein are compositions, methods, and systems useful in the prevention, management, or treatment of various conditions associated the lymphatic vasculature, including, but not limited to lymphedema. The disclosed methods and compositions are useful in reducing the activity of p53 in a subject at risk for or suffering from a disease or condition associated with lymphatic vasculature, including adults, children, infants, and embryos. Reduction in p53 activity may be achieve through reduction in one or more of p53 gene expression, p53 transcriptional activity, p53 DNA-binding affinity, etc. In many embodiments, the disease or condition is lymphedema, for example lymphedema associated with Milroy's disease, Klippel-Trenaunay and Cloves Syndromes. In many embodiments, treatment may involve administering a compound or pharmaceutically acceptable salt thereof to a subject in need thereof, exemplary compounds include, anti-p53 compounds, PFT, and PFT-β. | 2022-07-14 |
20220218675 | TREATMENT OF OCULAR DISEASE - The present invention is in the field of ocular disease therapy. In particular, the invention relates to a composition comprising pimecrolimus for use in the topical treatment of moderate to severe blepharitis, in particular in a patient group comprising subjects with a clinical diagnosis of moderate to severe blepharitis, wherein the subjects to be treated have signs and symptoms of moderate to severe blepharitis characterised by swelling of the eyelid margin, ocular debris and ocular discomfort. In particular, the present invention relates to an ophthalmic composition that shows a high patient acceptance and a clinically meaningful improvement in the signs and symptoms of treated patients. | 2022-07-14 |
20220218676 | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE - The present invention provides certain substituted chromane, isochromane, and dihydroisobenzofuran compounds of formula (I): | 2022-07-14 |
20220218677 | ARYLQUINOZILINE DERIVATIVES AS ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA - The present invention relates to α2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular arylquinolizine derivatives of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring. | 2022-07-14 |
20220218678 | USE OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL DERIVATIVES FOR TREATING CYSTIC FIBROSIS - The present invention relates to the use of agents, which are 1-phenyl-2-pyridinyl alkyl alcohol derivatives, for the prevention and/or treatment of cystic fibrosis in a subject, wherein the subject is characterized by at least one mutation in the gene encoding the CFTR protein, wherein the at least one mutation is causative for incorrect folding and/or processing of the CFTR protein. By the use of the compound according to the present invention, cystic fibrosis in the subject may be prevented or treated. The agent to be used according to the present invention has the capacity to restore the presence of the mutant CFTR protein at the cell surface, and thus act as CFTR correctors. The agent to be used according to the present invention may be administered to a subject in need thereof alone or in combination therapy with other agents, and is suitably administered by inhalation. | 2022-07-14 |
20220218679 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The present invention discloses compounds according to Formula I: | 2022-07-14 |
20220218680 | TREATMENTS OF HEREDITARY ANGIOEDEMA - The present invention relates to treatments of hereditary angioedema (HAE). In particular, the present invention provides on-demand treatments of hereditary angioedema (HAE) by orally administering a plasma kallikrein inhibitor to a patient in need thereof on-demand. Regular (or continuous) treatments of HAE are also provided. | 2022-07-14 |
20220218681 | COMPOUNDS AND THEIR METHODS OF USE - The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein. | 2022-07-14 |
20220218682 | COMPOSITIONS AND METHODS FOR TREATING CANCER - Provided herein are pharmaceutical compositions comprising an effective amount of an agent that inhibits EGFR signaling and izoniazid, which are useful for treating cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2022-07-14 |
20220218683 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF - Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described. | 2022-07-14 |
20220218684 | LIQUID NIMODIPINE COMPOSITIONS - Liquid compositions comprising nimodipine having improved nimodipine concentrations are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the liquid compositions of the present invention are also detailed herein. | 2022-07-14 |
20220218685 | COMPOSITION FOR TREATING EYE DISEASES - The present invention relates to a composition for treating eye diseases, wherein the composition comprises a pyrazole-based compound, which is a pharmacologically active substance, and a biodegradable polymer, so that a drug effectively reaches a posterior segment of an eyeball, while prolonging an action time of the drug administered into the eyeball. | 2022-07-14 |
20220218686 | ANTIARRHYTHMIC FORMULATION - Pharmaceutical compositions comprising an antiarrhythmic agent for treatment of a heart condition via inhalation. Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also disclosed. | 2022-07-14 |
20220218687 | Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use - Provided are compositions comprising a stable solution of an immune-mediated inflammatory disease (IMID) agent, such as an immunomodulatory imide drug (IMiD) including, but not limited to, lenalidomide (LLD). More particularly, embodiments relate to stable solutions of IMiDs for parenteral use. Methods of preparing stable solutions of IMiDs are also provided. In some embodiments, methods of treating inflammatory disorders and cancer(s) by parenteral use of stable IMiD solutions, and formulations thereof, are provided. | 2022-07-14 |
20220218688 | PYRIDYLPYRIDONE COMPOUNDS - The invention provides novel pyridylpyridone compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, type II diabetes, inflammatory disease, autoimmune diseases, neurodegenerative disorders, cardiovascular disorders and viral infections; | 2022-07-14 |
20220218689 | TRANSDERMAL TROPANE COMPOSITIONS AND METHODS FOR USING THE SAME - Aspects of the invention include transdermal delivery devices for delivering a tropane active agent to a subject. Also provided are methods of using the subject transdermal delivery devices, as well as kits containing one or more of the transdermal delivery devices. | 2022-07-14 |
20220218690 | MONTELUKAST SALTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - The present invention relates to salts of Montelukast with β2 adrenergic agonists, pharmaceutical compositions containing the same and the use thereof in the treatment of respiratory inflammatory pathologies, obstructive pathologies and allergen-induced airway dysfunctions. The invention further relates to the process for preparing said salts. | 2022-07-14 |
20220218691 | COMBINATIONAL USES OF NITROXOLINE AND ITS ANALOGUES WITH CHEMOTHERAPIES AND IMMUNOTHERAPIES IN THE TREATMENT OF CANCERS - Novel combination therapies involving nitroxoline, its analogue or pharmaceutically acceptable salt thereof with at least one additional anti-cancer chemotherapy or immunotherapy agent are described. Related kits, pharmaceutical compositions and methods of production are also described. | 2022-07-14 |
20220218692 | COMBINATIONAL USES OF NITROXOLINE AND ITS ANALOGUES WITH CHEMOTHERAPIES AND IMMUNOTHERAPIES IN THE TREATMENT OF CANCERS - Novel combination therapies involving nitroxoline, its analogue or pharmaceutically acceptable salt thereof with at least one additional anti-cancer chemotherapy or immunotherapy agent are described. Related kits, pharmaceutical compositions and methods of production arlinee also described. | 2022-07-14 |
20220218693 | IMMUNE CHECKPOINT INHIBITOR COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE - Provided is a method for using a STAT3 inhibitor which exhibits an excellent antitumor effect. An antitumor agent comprises a quinoline carboxamide derivative of formula (I) below or a salt thereof as an active ingredient, and is administered in combination with an immune checkpoint inhibitor. The antitumor agent is administered before the administration of the immune checkpoint inhibitor. | 2022-07-14 |
20220218694 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS ASSOCIATED MUTATIONS - The present invention includes methods for treating a human patient with Crenolanib, wherein the human patient is suffering from a FLT3 mutated leukemia, the method comprising: determining that the human patient has a poor prognosis by: obtaining or having obtained a leukemia biological sample and performing or having performed a genotyping assay on the biological sample to determine that the human patient has both a mutated FLT3 or a constitutively active FLT3 mutant and one or more driver mutations in one or more epigenetic regulator proteins that results in a loss of normal function of the epigenetic regulator proteins which, indicates that the patient has a poor prognosis; and administering to the patient determined to have the poor prognosis a therapeutically effective amount of Crenolanib, or a pharmaceutically acceptable salt thereof having the formula: | 2022-07-14 |